Pharmafile Logo
Pharmafocus logo
Advanced Search

Aspire Pharma acquires Cenoté Pharma

March 11, 2024
Business Services Aspire Pharma, Cenoté Pharma, Pharmacy, acquisition

Aspire Pharma has announced that it has successfully acquired Cenoté Pharma as part of its plan to supplement its growth …

News

BeiGene’s Brukinsa gains FDA accelerated approval for follicular lymphoma treatment

March 8, 2024
Medical Communications BeiGene, Brukinsa, FDA, Oncology, follicular lymphoma

BeiGene has announced that the US Food and Drug Administration (FDA) has granted accelerated approval to Brukinsa (zanubrutinib) for the …

News

Roche shares data on novel solution for continuous glucose monitoring

March 8, 2024
Research and Development Diabetes, Medical device, Roche, continuous glucose monitoring, diabetes

Roche has shared the latest data on its novel solution for continuous glucose monitoring (CGM), including a CGM sensor and …

News

GSK shares results from phase 3 trial for Blenrep for treatment of multiple myeloma

March 7, 2024
Research and Development Blenrep, GSK, Oncology, clinical trial, multiple myeloma

GSK has announced positive results from an interim analysis of the DREAMM-8 phase 3 head-to-head trial which assesses Blenrep (belantamab …

News

Gilead and Merck share data from phase 2 trial of HIV treatment

March 7, 2024
Research and Development Gilead Sciences, HIV, HIV/AIDS, Merck, clinical trials

Gilead Sciences and Merck (known as MSD outside of the US and Canada) have announced results from the phase 2 …

News

Measles: the UK’s next epidemic?

March 6, 2024
MMR, measles, vaccines

Recently, the UK has seen a rapid increase in the number of cases of measles, along with a drop in …

Feature

FDA approves Sandoz’s denosumab biosimilars

March 6, 2024
Medical Communications FDA, Jubbonti, Musculo-skeletal disorder, Sandoz, Wyost, denosumab

Sandoz has announced that the US Food and Drug Administration (FDA) has approved Wyost (denosumab-bbdz) and Jubbonti (denosumab-bbdz), which are …

News

Regenxbio announces initial efficacy data from phase 1/2 AFFINITY DUCHENNE trial

March 6, 2024
Research and Development Duchenne Muscular Dystrophy, Musculo-skeletal disorder, Regenxbio, clinical trial

Regenxbio has announced additional interim safety data from its phase 1/2 AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne …

News

GSK’s Jemperli recommended by NICE for endometrial cancer treatment

March 5, 2024
Medical Communications GSK, Jemperli, NICE, Oncology, endometrial cancer

GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) …

News
chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

March 5, 2024
Musculo-skeletal disorder, Novartis, Zolgensma, sma, spinal muscular atrophy

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma (onasmenogene abeparvovec), for the treatment …

News

FDA approves J&J’s Rybrevant with chemotherapy for NSCLC treatment

March 4, 2024
Medical Communications FDA, Johnson & Johnson, NSCLC, Oncology, Rybrevant

Johnson & Johnson have announced that the US Food and Drug Administration (FDA) has approved Rybrevant (amibantamab-vmjw) following a priority …

News
louis-reed-pwckf7l4-no-unsplash_5

EMA validates two applications for datopotamab deruxtecan for cancer treatments

March 4, 2024
Medical Communications CHMP, Daiichi Sankyo, EMA, Oncology, datopotamab deruxtecan

AstraZeneca has announced that the European Medicines Agency (EMA) has validated to marketing authorisation applications (MAAs) for AstraZeneca and Daiichi …

News

Cardiff Oncology doses first patient in colorectal cancer trial

March 1, 2024
Research and Development Cardiff Oncology, Oncology, clinical trial, colorectal cancer

Cardiff Oncology has announced that it has dosed the first patient in its randomised first-line phase 2 trial, CRDF-004, for …

News

Viracta Therapeutics completes enrolment for T-cell lymphoma cohort in NAVAL-1 trial

March 1, 2024
Medical Communications Oncology, Viracta Therapeutics, lymphoma

Viracta Therapeutics has announced that it has completed stage 2 enrolment into the relapsed or refractory (R/R) Epstein-Barr virus-positive (EBV+) …

News

AstraZeneca’s Voydeya recommended for approval in EU by CHMP

February 29, 2024
Medical Communications AstraZeneca, CHMP, EMA, Haematology, Voydeya

AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) by the Committee …

News

Spero Therapeutics’ bacterial infection treatment gains FDA IND clearance

February 29, 2024
Medical Communications FDA, Infections and infestations, Spero Therapeutics, bacterial infections, investigational new drug

Spero Therapeutics has announced that it has gained US Food and Drug Administration (FDA) clearance for the investigational new drug …

News

Viatris and Idorsia enter research and development collaboration

February 28, 2024
Research and Development Idorsia, Pharmacy, Viatris, acute myocardial infarction, systemic lupus erythematosus

Viatris and Idorsia have announced that they have entered into agreements for a significant global research and development collaboration. Under …

News

Amneal and Zambon Biotech enter agreement for Parkinson’s treatment

February 28, 2024
Research and Development Amneal pharmaceuticals, Neurology, Parkinson's disease, Zambon Biotech, licensing agreement

Amneal Pharmaceuticals has announced that it has entered into an exclusive licensing agreement with Zambon Biotech for IPX204 in the …

News

GSK shares positive results from phase 3 trial for gonorrhoea treatment

February 27, 2024
Research and Development GSK, Infections and infestations, antibiotic, clinical trial, gonorrhoea

GSK has announced positive headline results from its phase 3 EAGLE-1 trial for gepotidacin, its potential first-in-class oral antibiotic with …

News

Amgen opens new biomanufacturing facility in Ohio, US

February 27, 2024
Manufacturing and Production Amgen, Biomanufacturing, Manufacturing Facility, Ohio, Pharmacy, US

Amgen has announced that it has opened a new manufacturing site in Central Ohio, US. This will be the latest …

News

Latest content

Mirum Pharmaceuticals publishes phase 3 MARCH maralixibat data in The Lancet

May 8, 2024

Circular Genomics reveals study results into predicting patient response to SSRI antidepressant treatment

May 8, 2024

Gossamer Bio and Chiesi Group enter into international collaboration to commercialise Seralutinib

May 7, 2024

Broken String Biosciences and the Francis Crick Institute collaborate on ALS research

May 7, 2024

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024